Imexhs Ltd · ASX:IME
Imexhs — Investor Presentation (April 2020)
24 slides from Imexhs's investor presentation, Apr 1, 2020
Slide 1: IMEXHS: Built by physicians for physicians
For personal use only IMEXHS Built by physicians for physicians Authorised for release by Dr German Arango Bonnet (Chief Executive Officer), 1 April 2020 “Confidential and Proprietary. Copyright by IMEXHS. All Rights Reserved.”
Slide 2: Imaging software solutions enhancing the medical imaging experience
For personal use only lmaging software solutions enhancing the medical imaging experience, for patients and doctors.
Slide 3: COVID-19 Update
COVID-19 UPDATE • No material impact on operations For personal use only • No immediate impact to revenue with service to existing financially-secure customers in the health care sector - majority of SaaS contracts are long term (5-7 years) and fixed price. • Overall current net impact not material
Slide 4: Innovative Provider of End-to-End Imaging Software Solutions
Innovative Provider of End-to-End Imaging Software Solutions For personal use only • Next Generation multi-modality cloud • Global RIS/PACS market of $5.8b. with based Medical Imaging Software a CAGR of 7.4% • Scalable SaaS subscription model with • Focussed on Recurring Revenue 227 customers global
Slide 5: Our Portfolio
Our Portfolio RADIOLOGY For personal use only IMAGING SOFTWARE PATHOLOGY Enterprise Imaging IMAGING SOFTWARE CARDIOLOGY IMAGING SOFTWARE
Slide 6: How we do it
How we do it For personal use only Scan Scheduled via our platforms Uploaded to Our Platforms Archived on our cloud- based platforms Manages Billing } 1) Business Intelligence 2) Statistical Data 2. Patient 4. Referring 5. Billing 1. Physician 3. Radiologist Physician reviews (Publically requests re
Slide 7: Sustainable Business Model
Sustainable Business Model For personal use only Sales Revenue Mix Long term contracts ~5 Recurring $6.6m 86% YEAR One of $1.1m 14% CONTRACTS Monthly subscription fees Recurring Revenue Mix Total Contract Value (March 2020) SaaS Hardware 24% 76% $25.2m
Slide 8: Strong Growth Profile
Strong Growth Profile For personal use only $7.1m 124% $142m 34% Cash & cash ARR CAGR Total pipeline FY19 sales revenue equivalents since inception growth on pcp +136% +22.5% +85% >95% Recurring Revenue growth TCV Net Assets growth Customer on pcp growth on pcp on pcp retention
Slide 9: Expanding International Footprint
Expanding International Footprint 23 distributors For personal use only SPAIN USA 15 countries HONDURAS MEXICO NICARAGUA >270 sites EL SALVADOR PANAMA AUSTRALIA COSTA RICA COLOMBIA >600 radiologists ECUADOR PERU BRAZIL BOLIVIA PARAGUAY CHILE URUGUAY ARGENTINA IMEXHS currently operating Agreement bei
Slide 10: Track Record of growing Annual Recurring Revenue
Track Record of growing Annual Recurring Revenue For personal use only • High level of customer retention supports Annual ANNUALISED RECURRING REVENUE Recurring Revenue (ARR) of A$9.2m (March 2020) 3month Series1 Series2 Interval • Strong weighted pipeline of A$70m (March 2020) 10 Millions 9 8 7 • R
Slide 11: Operational Growth
Operational Growth For personal use only Increase in Studies Stored Images 2019 25.7m +94% >200m 2018 13.2m Head Count Increase >5 Peta Bytes Of data 2019 2018 82px 125px +52%
Slide 12: Strong revenue pipeline supports growth runway
Strong revenue pipeline supports growth runway For personal use only WEIGHTED SALES PIPELINE A$m 0 10 20 30 40 50 60 70 80 Series1 Series2 Series3
Slide 13: Significant Global RIS/PACS Market in Radiology Alone
Significant Global RIS/PACS Market in Radiology Alone For personal use only 7.4% CAGR 2019-2027 $4.7bn PACS $950m RIS https://www.marketwatch.com/press-release/2019-pacs-and-ris-market-insight-outlook-industry-analysis-and-future-forecast-till-2027-2019-08-09?mod=mw_quote_news
Slide 14: Financial Summary
For personal use only Financial Summary
Slide 15: FY19 Income Statement
FY19 Income Statement For personal use only Consolidated FY19 FY18 • Annual Recurring Revenue (ARR) of $8.5m at December 2019 $'000 $'000 % has increased to $9.2m at March 2020 due to recent contract Revenues wins & increases, and FX impact Recurring Sales 6,603 2,798 136 One off Sales 1,124 2,982 (
Slide 16: FY19 Financial Position
FY19 Financial Position For personal use only Consolidated FY19 FY18 $'000 $'000 % • Strong Financial Position with $7.1m cash, provides Cash 7,150 2,445 192 significant flexibility Trade & other receivables 3,654 3,881 (6) Inventories 107 811 (87) • Cash conversion improving with trade & other rece
Slide 17: Summary & Outlook
For personal use only Outlook Summary &
Slide 18: Investment Summary
Investment Summary For personal use only LEADING SALES FINANCIAL DE-RISKED PROVEN TECH PIPELINE STRENGTH HIGH MARGIN SCALABLE CUSTOMER GROWING STRONG FOCUSSED POSITION Recurring Scalable business Software Significant Ability to contract able to rapidly developed by revenue maximise revenues from exp
Slide 19: Strategic Priorities
Strategic Priorities For personal use only Geographic Expansion Product Development Multiple Verticals • Increased penetration • AI product development • Medical – Radiology, in LATAM countries Pathology and Cardiology • Enhanced AI image library • Developed markets • Security strategy • Clinical Tr
Slide 20: Thank You
THANK YOU For personal use only www.imexhs.com
Slide 21: Award winning company
Award winning company For personal use only 2013 2018 2019 • 1st Place CEEI European • Finalists as leading Union Awards for technology • FDA clearance. Business Model. development • 1st Place - Digital Transformation companies. Awards for Innovative solutions. • 1st Place - SiiM Hackathon Peoples C
Slide 22: The Problem / Our Solution
For personal use only The Problem Our Solution • Analog • Digital • On premise exclusive • Cloud • Inefficient • Efficient • Not adaptable • Flexible • Limited Accessibility • Accessible • Expensive • Affordable • Not Scalable • Scalable • Siloed • Interoperable • Studies delivery • Teleradiology •
Slide 23: The Problem
The Problem For personal use only On premise Limited Analog Exclusive Inefficient Not Adaptable Accessibility Expensive Not Scalable Siloed Studies delivery Environmentally Unfriendly
Slide 24: Our Solution
Our Solution For personal use only Digital Cloud Efficient Flexible Accessible Affordable Scalable Interoperable Teleradiology Environmentally Friendly